Clinical trials: Antiviral
HIV Infections
A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC
To determine the safety, toxicity, pharmacokinetic profile, and antiretroviral activity of atevirdine mesylate ( U-87201E ) in HIV-infected patients.
- Trial name
- NCT00000753
- Testing
- Atevirdine mesylate, Zidovudine, Zalcitabine
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections With Multi Drug Resistant Virus
Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance
In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance.
- Trial name
- NCT04648280
- Testing
- Fostemsavir
- Where
- 8 sites in United States, Brazil and 1 more
- Volunteers
- 60 people
- Sponsor
- PENTA Foundation
Australia Antigen Positive, Hepatitis B
Optimization of Antiviral Therapy of Chronic HBV Infection
Along with the improvement of the accuracy of detection of HBV serological markers, the optimization of antiviral therapy for patients with chronic hepatitis B (CHB) infection becomes feasible.
- Conditions
- Australia Antigen Positive, Hepatitis B, Adverse Effects
- Trial name
- NCT01623778
- Testing
- Interferon Alfa-2a add on ADV
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Changhai Hospital
COVID-19
The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19
The coronavirus disease 2019 (COVID-19) has spread rapidly and caused a global pandemic, as defined by the WHO, within a short period of time.
- Trial name
- LUSZ_SCORE (NCT05848427)
- Testing
- LUSZ P
- Where
- 2 sites in Lebanon
- Volunteers
- 1,000 people
- Sponsor
- Lebanese University
Hepatitis C
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant…
- Trial name
- NCT03268317
- Volunteers
- 100 people
- Sponsor
- Assiut University
HIV Infections
A Study of Disease Progression and Anti-HIV Treatments
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen.
- Trial name
- NCT00001068
- Testing
- Lamivudine
- Where
- 41 sites in United States, Puerto Rico and 1 more
- Volunteers
- 210 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies.
- Trial name
- NCT00002210
- Testing
- Delavirdine mesylate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pharmacia and Upjohn
HBV
Antiviral Therapy in Infants With HBV Infection
This study was a multicenter, prospective randomized controlled clinical study. A total of 60 HBV-infected infants with ALT ≤5 times the upper limit of normal (ULN) and without pathological jaundice were enrolled and randomized…
- Trial name
- NCT06503796
- Testing
- Lamivudine, Interferon
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
Hepatitis B Virus (HBV)
Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection
The primary purpose of the study is to evaluate the effectiveness, safety, and tolerability of tenofovir disoproxil fumarate (TDF) in adolescents (aged 12-17 years) with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT00734162
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- 21 sites in United States, Bulgaria and 5 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in South Africa.
- Trial name
- ENABLE 1 (NCT07655128)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl)
- Volunteers
- 87 people
- Sponsor
- Hospital Universitario 12 de Octubre
Cytomegalovirus Retinitis, HIV Infections
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component
To evaluate the relative effectiveness and safety of foscarnet versus ganciclovir for the treatment of cytomegalovirus (CMV) retinitis in people with AIDS; to evaluate the relative effect on survival of the use of these two…
- Trial name
- NCT00000665
- Testing
- Foscarnet sodium, Ganciclovir
- Where
- 9 sites in United States
- Volunteers
- 240 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis B
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection
The goals of this clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in…
- Trial name
- NCT02932150
- Testing
- TAF
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 150 people
- Sponsor
- Gilead Sciences
Patternsof Liver Diseasesadmissions After Era of DAAS
Difference in Patterns of Liver Diseases Related Admissions After the Era of DAAS
Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular carcinoma Hepatitis is defined as inflammation of…
- Trial name
- NCT05284916
- Testing
- liver diseases admissions
- Volunteers
- 200 people
- Sponsor
- Sohag University
Herpes Simplex, HIV Infections
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine
To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to…
- Trial name
- NCT00000635
- Testing
- Trifluridine, Bacitracin zinc/Polymyxin B sulfate
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus (CMV)
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of…
- Trial name
- NCT05319353
- Testing
- Maribavir
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 80 people
- Sponsor
- Takeda
Herpes Labialis
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
- Trial name
- NCT02265913
- Testing
- Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference)
- Where
- United States
- Volunteers
- 4,076 people
- Sponsor
- Padagis LLC
HIV-1, HIV Infections
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), safety, tolerability and antiviral activity to support dose recommendations of TMC114…
- Trial name
- NCT00355524
- Testing
- TMC114, Ritonavir
- Where
- 22 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients
To investigate the safety of thymic humoral factor (THF gamma 2), its effect on HIV load based on at least a 75 percent decrease in HIV quantitative PCR RNA copies/ml, and its persistence when administered in combination with an…
- Trial name
- NCT00002435
- Testing
- Thymic Humoral Factor, Zidovudine
- Where
- 10 sites in United States
- Sponsor
- Pharmacia
HIV Infections
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection
AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled. Original design: To determine whether the experimental drug recombinant CD4 (rCD4), which is produced through genetic engineering technology, is safe and…
- Trial name
- NCT00000984
- Testing
- CD4 Antigens
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy
The purpose of this study was to evaluate the safety and antiviral activity to promote clearance of HIV-1 infected cells of VRC01 in infants with HIV beginning combination antiretroviral therapy (cART).
- Trial name
- NCT03208231
- Testing
- VRC01, Combination Antiretroviral Therapy (cART)
- Where
- 7 sites in Botswana, Brazil and 2 more
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)